title: Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
abstract: Stage D2 prostate cancer patients with pulmonary metastases and absence of detectable metastases in bones are quite rare and almost always show accompanying favorable and long-term clinical response to hormone therapy. We present a case of a patient with pulmonary metastases caused by prostate cancer who experienced 13-year complete clinical response to GnRH analogues and we discuss the possible implications of host tissue-metastatic cancer cell interactions in pulmonary metastases and clinical response to hormone depletion therapy.
authors.affiliation: Department of Experimental Physiology, Medical School of Athens, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Behrakis
authors.forename: M
authors.initials: M
authors.lastname: Koutsilieris
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002064:Buserelin / Q000627:therapeutic use*; D005500:Follow-Up Studies; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D013739:Testosterone; D017430:Prostate-Specific Antigen; D002064:Buserelin